vs
Side-by-side financial comparison of Apellis Pharmaceuticals, Inc. (APLS) and CAVA GROUP, INC. (CAVA). Click either name above to swap in a different company.
CAVA GROUP, INC. is the larger business by last-quarter revenue ($280.6M vs $199.9M, roughly 1.4× Apellis Pharmaceuticals, Inc.). CAVA GROUP, INC. runs the higher net margin — 6.5% vs -29.5%, a 36.0% gap on every dollar of revenue. On growth, CAVA GROUP, INC. posted the faster year-over-year revenue change (20.2% vs -5.9%). CAVA GROUP, INC. produced more free cash flow last quarter ($19.2M vs $-14.3M).
Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing targeted therapies that modulate the complement system to address serious unmet medical needs. Its core products target ophthalmic conditions like geographic atrophy secondary to age-related macular degeneration, as well as rare hematological and autoimmune disorders, with primary operations in the United States and European markets.
Cava, also referred to as Cava Grill, is an American Mediterranean fast casual restaurant chain with locations across the United States. Cava is owned by the publicly traded Cava Group, which purchased Zoës Kitchen in August 2018. The combined company is the largest restaurant operator in the Mediterranean category in the U.S. restaurant industry. Cava also produces a line of Mediterranean dips, spreads, and dressings that are sold in grocery stores across the US. As of May 2023, all Zoës Kit...
APLS vs CAVA — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $199.9M | $280.6M |
| Net Profit | $-59.0M | $18.4M |
| Gross Margin | — | — |
| Operating Margin | -25.6% | 7.0% |
| Net Margin | -29.5% | 6.5% |
| Revenue YoY | -5.9% | 20.2% |
| Net Profit YoY | -62.2% | -7.0% |
| EPS (diluted) | $-0.40 | $0.16 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $199.9M | — | ||
| Q3 25 | $458.6M | $280.6M | ||
| Q2 25 | $178.5M | $331.8M | ||
| Q1 25 | $166.8M | — | ||
| Q4 24 | $212.5M | — | ||
| Q3 24 | $196.8M | $233.5M | ||
| Q2 24 | $199.7M | $259.0M | ||
| Q1 24 | $172.3M | — |
| Q4 25 | $-59.0M | — | ||
| Q3 25 | $215.7M | $18.4M | ||
| Q2 25 | $-42.2M | $25.7M | ||
| Q1 25 | $-92.2M | — | ||
| Q4 24 | $-36.4M | — | ||
| Q3 24 | $-57.4M | $19.7M | ||
| Q2 24 | $-37.7M | $14.0M | ||
| Q1 24 | $-66.4M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 26.7% | ||
| Q2 24 | — | 25.2% | ||
| Q1 24 | — | — |
| Q4 25 | -25.6% | — | ||
| Q3 25 | 48.7% | 7.0% | ||
| Q2 25 | -18.6% | 4.7% | ||
| Q1 25 | -50.0% | — | ||
| Q4 24 | -12.3% | — | ||
| Q3 24 | -24.0% | 6.9% | ||
| Q2 24 | -14.7% | 3.6% | ||
| Q1 24 | -36.0% | — |
| Q4 25 | -29.5% | — | ||
| Q3 25 | 47.0% | 6.5% | ||
| Q2 25 | -23.6% | 7.7% | ||
| Q1 25 | -55.3% | — | ||
| Q4 24 | -17.1% | — | ||
| Q3 24 | -29.2% | 8.5% | ||
| Q2 24 | -18.9% | 5.4% | ||
| Q1 24 | -38.5% | — |
| Q4 25 | $-0.40 | — | ||
| Q3 25 | $1.67 | $0.16 | ||
| Q2 25 | $-0.33 | $0.22 | ||
| Q1 25 | $-0.74 | — | ||
| Q4 24 | $-0.30 | — | ||
| Q3 24 | $-0.46 | $0.17 | ||
| Q2 24 | $-0.30 | $0.12 | ||
| Q1 24 | $-0.54 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $466.2M | $290.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $370.1M | $750.7M |
| Total Assets | $1.1B | $1.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $466.2M | — | ||
| Q3 25 | $479.2M | $290.2M | ||
| Q2 25 | $370.0M | $289.4M | ||
| Q1 25 | $358.4M | — | ||
| Q4 24 | $411.3M | — | ||
| Q3 24 | $396.9M | $343.7M | ||
| Q2 24 | $360.1M | $329.1M | ||
| Q1 24 | $325.9M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
| Q4 25 | $370.1M | — | ||
| Q3 25 | $401.2M | $750.7M | ||
| Q2 25 | $156.3M | $726.2M | ||
| Q1 25 | $164.2M | — | ||
| Q4 24 | $228.5M | — | ||
| Q3 24 | $237.1M | $595.4M | ||
| Q2 24 | $264.3M | $580.8M | ||
| Q1 24 | $266.7M | — |
| Q4 25 | $1.1B | — | ||
| Q3 25 | $1.1B | $1.3B | ||
| Q2 25 | $821.4M | $1.2B | ||
| Q1 25 | $807.3M | — | ||
| Q4 24 | $885.1M | — | ||
| Q3 24 | $901.9M | $1.0B | ||
| Q2 24 | $904.5M | $1.0B | ||
| Q1 24 | $831.9M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-14.2M | $60.3M |
| Free Cash FlowOCF − Capex | $-14.3M | $19.2M |
| FCF MarginFCF / Revenue | -7.1% | 6.8% |
| Capex IntensityCapex / Revenue | 0.1% | 14.7% |
| Cash ConversionOCF / Net Profit | — | 3.28× |
| TTM Free Cash FlowTrailing 4 quarters | $45.0M | $49.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-14.2M | — | ||
| Q3 25 | $108.5M | $60.3M | ||
| Q2 25 | $4.4M | $38.6M | ||
| Q1 25 | $-53.4M | — | ||
| Q4 24 | $19.4M | — | ||
| Q3 24 | $34.1M | $48.9M | ||
| Q2 24 | $-8.3M | $38.4M | ||
| Q1 24 | $-133.0M | — |
| Q4 25 | $-14.3M | — | ||
| Q3 25 | $108.3M | $19.2M | ||
| Q2 25 | $4.4M | $2.7M | ||
| Q1 25 | $-53.4M | — | ||
| Q4 24 | $19.3M | — | ||
| Q3 24 | — | $22.7M | ||
| Q2 24 | $-8.4M | $4.7M | ||
| Q1 24 | $-133.3M | — |
| Q4 25 | -7.1% | — | ||
| Q3 25 | 23.6% | 6.8% | ||
| Q2 25 | 2.5% | 0.8% | ||
| Q1 25 | -32.0% | — | ||
| Q4 24 | 9.1% | — | ||
| Q3 24 | — | 9.7% | ||
| Q2 24 | -4.2% | 1.8% | ||
| Q1 24 | -77.3% | — |
| Q4 25 | 0.1% | — | ||
| Q3 25 | 0.0% | 14.7% | ||
| Q2 25 | 0.0% | 10.8% | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | 11.2% | ||
| Q2 24 | 0.0% | 13.0% | ||
| Q1 24 | 0.2% | — |
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | 3.28× | ||
| Q2 25 | — | 1.50× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.48× | ||
| Q2 24 | — | 2.74× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
CAVA
| Restaurant Revenue | $278.2M | 99% |
| Rewards | $2.8M | 1% |
| CPG Revenue And Other | $2.4M | 1% |
